[ topical analysis ] propaganda analysis
Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel ... PharmaLive: Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation
Search Criteria:
Search In:
TODAY ON PHARMALIVE.COM
Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation
Share
Acceptance of Investigational New Drug Application is another significant milestone in the effort to address the significant need for a therapy for acute repetitive seizures outside of the hospital setting.
SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures. Following initial pre-IND discussions with FDA in late 2011, Neurelis filed the IND based upon the encouraging human pharmacokinetic results seen when comparing absolute bioavailability of NRL-1 relative to intravenous diazepam administration in healthy subjects. In the IND submission, Neurelis formalized plans for the remaining clinical and non-clinical requirements that FDA agreed to in the pre-IND discussions which will support the submission for marketing approval.
"We are encouraged with our interactions with the FDA and the formalization of our development plan for NRL-1. The acceptance of the IND is a significant step in advancing the development of this important therapy," stated David F. Hale, Chairman of Neurelis. "We believe that NRL-1 has demonstrated a pharmacokinetic profile and bioavailability which has not been seen with previous attempts at the intranasal delivery of benzodiazepines. With the successful development of NRL-1 and approval from the FDA and other regulatory agencies, we look forward to making this product available to those patients who have epilepsy and suffer from acute repetitive seizures."
About NRL-1
NRL-1 (intranasal diazepam) is a proprietary formulation of diazepam delivered via a commercially available nasal sprayer. It is being developed for the management of patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity. There are over 2.7 million people with epilepsy in the United States with approximately 200,000 new patients diagnosed each year. It is estimated that between 30% to 40% of these patients are uncontrolled on oral therapy and are at-risk for acute breakthrough seizures. Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death.
Presently, the only product approved for the treatment of acute repetitive seizures outside of the hospital setting, is a rectally administered formulation of diazepam called Diastat.. Because of its rectal mode of administration, Diastat. has been primarily relegated to use in younger pediatric patients (usually less than 10 years of age). The majority of patients with acute repetitive seizures; however, are currently seen in emergency rooms and treated with intravenous benzodiazepines. Most of these patients are admitted to the hospital. This represents a significant component of the estimated $15 billion annual economic burden on the system to treat epilepsy in the U.S. Intranasal diazepam would provide a more convenient alternative to either rectal administration of Diastat. or the need to visit the emergency room for intravenous administration of drugs.
About Neurelis
Neurelis, Inc. is a San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system ("CNS") market. Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.
Contact: David F. Hale
Email: salaimo@neurelis.com
SOURCE Neurelis, Inc.
Printer Friendly Version Forward to a Friend
Get Instant Access to our News Archive
For more than 20 years, executives like you have relied on Canon Communications Pharmaceutical Media Group for the business, marketing, and clinical research information needed to make informed business decisions. NewsPass gives you access to an array of integrated information services - information that is critical to your success and the success of your organization.
Login or activate your NewsPass Account now!
Ask The Experts
MedAdNews
Which pharma or biotech company, in your opinion, uses offshoring ...
R&D Directions
What are some recommendations on "fit-for-purpose" best practices ...
How feasible is the nasal route to deliver peptides into the brain ...
Have tangible strides been made in using PET scanning to study ...
Supplements
MedAdNews
Guide to Pharmaceutical Marketing and Interactive Services
Download
Podcasts
BIO's Big Ideas with James C. Greenwood
Download
The Government and Drug Development with James C. Greenwood
Download
Politics, Approvals, and PhRMA's Future with John Castellani
Download
Meet Your New President with John Castellani
site license
Top Japanese Pharmaceutical Companies & Their Pipelines
With this PharmaLive Special Report:
* Understand the unique challenges facing Japanese pharma companies and strategies being employed to compete in the global market
* Understand technological advances as well as challenges and opportunities driving growth in these sectors
* Pinpoint partnership, acquisition, and investment opportunities that could bolster your company's product portfolio
ORDER NOW - Save $50!
Learn More
Analytical Reports
News Archive
Site License/RSS
eKnowledgeBase
Only on PharmaLive.com
CROs are a key cog in centralized data push
Q&A: CROs and site selection
Reinventing the account manager: Why a payer-dominated marketplace requires new skills training
MedAdNews Insider
Digital marketing in pharma: more than just an 'add-on' to current strategy
A new approach to improving adherence and compliance: focus on pharmacists' perspectives
R&D Directions Insider
Metabolomic profiling could benefit personalized med efforts
'Lower costs and better outcomes are mission critical' for sponsors
Subscriber registration
Purchase a subscription
Forget your password
Need help?
Your account details
Order back issues
Renew subscription
Advertise
| re:1.45 st:0.01 fo:0 s:0.01 d:0 c:0 db:0.031 a:0.59 m:0.43 t:7.64 (f) |
text of article used for CRITICAL ANALYSIS, under FAIR USE provisions of the Copyright Act of 1976, 17 U.S.C. § 107, et al.
| 
